ERC Consolidator Grant · 2021
Multiple myeloma (MM) is a bone marrow malignancy that is always preceded by asymptomatic precursor conditions, monoclonal gammopathy of undetermined significance (MGUS) or smoldering MM (SMM). SMM is a more advanced precursor and is associated with a high risk of progression to MM. More than 94% of MM cases are diagnosed when already at the stage of full-blown malignancy and therefore do not benefit from the impact of early treatment. Recent studies indicate a benefit of early treatment but all prior SMM studies are based on patients diagnosed due to other medical issues and are therefore biased. There are important and urgent questions on the role of screening and early treatment in SMM.…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.